| Objectives: The current study evaluated the effects of green coffee extract (GCE) on serum lipid profile and
adiponectin levels in patients with nonalcoholic fatty liver disease (NAFLD).
Design: This randomized, double-blind, placebo-controlled clinical trial was conducted on NAFLD patients aged
20–60 years and body mass index (BMI) of 25−35 kg/m2.
Setting: Patients were recruited from the Bahman poly-clinic (Neyshabur, Iran) between January and June 2016.
Interventions: The study subjects were randomly assigned to receive a daily dose of 400 mg GCE (n=24) or
placebo (n=24) for eight weeks.
Main outcome measures: Serum liver enzyme levels, lipid profile, adiponectin concentrations, and hepatic steatosis
grade were measured for all patients at baseline and the end of the trial.
Results: GCE supplementation significantly reduced BMI [mean difference (MD): −0.57 and 95 % confidence
interval (CI): −0.84 to −0.29, P < 0.001] and increased serum high-density lipoprotein cholesterol (MD: 7.06,
95 % CI: 0.25–13.87, P < 0.05) compared to the control group. Serum total cholesterol decreased significantly
within the GCE group (MD: −13.33, 95 % CI: −26.04 to −0.61, P < 0.05). Triglyceride levels reduced significantly
in GCE group compared to the placebo group (MD: -37.91; 95 % CI: −72.03 to −3.80; P=0.03).
However, this reduction was not significant when was further adjusted for mean changes in BMI and daily
energy intake (MD: -23.43; 95 % CI: −70.92 to 24.06; P=0.32). Hepatic steatosis grade, liver enzymes, and
adiponectin levels did not show significant differences between the two groups after the intervention.
Conclusions: GCE supplementation improved serum lipid profile and BMI in individuals with NAFLD. GCE may
be useful in controlling NAFLD risk factors. |